Dennis Keefe
Seminars
Monday 1st December 2025
Rethinking the Delivery of Complement-Based Therapeutics to Ensure Complement Moderators are Reaching the Correct Targets in the Appropriate Quantities
2:30 pm
Join this workshop to deepen your understanding of the approaches being used to overcome the challenges in effectively delivering complement mediators to their target tissues and discuss optimal dosages for complement-based therapeutics for different organs.
- Understanding organ-specific differences and their implications for developing effective complement targeted therapies from a drug delivery perspective
- Exploring alternatives to traditional delivery methods such as ocular injection and addressing the unique architecture and environment of the eye when designing delivery methods.
- Debating the optimal uses for systemic vs local complement targeting considering the potential for broad immune suppression
- Examining the rationale for, and challenges of selectively modulating complement activity at the local site of disease given the organ-specific nature of complement-mediated diseases
- Reviewing innovative methods to concentrate complement inhibitors at the target organ or tissue, e.g. podocytes in C3G
- Discussing technologies and modalities that improve targeted delivery such as novel modalities like gene therapies, siRNA and small molecules for maximum therapeutic effect whilst reducing the systemic side effects associated with broadly acting complement inhibitors
- Assessing trade-offs between oral, IV and localized injection in achieving sitespecific targeting to enhance efficacy and mitigate systemic ‘black box’ warnings whilst considering patient experience and adherence
Wednesday 3rd December 2025
Panel Discussion: Discussing the Next-Generation of Novel Modalities to be Used for Enhanced Delivery & Broader Impact in CNS & Ophthalmic Indications
12:00 pm
- Addressing the critical challenge of achieving sufficient complement inhibitor exposure in the CNS, a major reason for past failures with peripherally acting drugs
- Exploring novel delivery modalities like gene therapy, shuttle technologies that are in early development, to unlock the therapeutic potential of complement inhibition neurodegenerative diseases
- Highlighting the significant appeal and ongoing development of gene therapies for chronic ophthalmic conditions driven by complement